In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Drug-Eluting Stents, How Full is the Cup?

Executive Summary

At this year's Paris Course on Revascularization, much of the discussion turned to drug-eluting stents. An important new clinical trial underscored the technology's value in reducing or eliminating restenosis. But with the product now commercially available in Europe, economic concerns are beginning to be heard loudly.
Advertisement

Related Content

At TCT, A New Vision of the Device Industry
At TCT, A New Vision of the Device Industry
Two Cheers for Evidence-Based Medicine
The Device Industry's Rx Marketing Dilemma
The Device Industry's Rx Marketing Dilemma
LuMend's Breakthrough Break Out
Drug Stents: J&J Innovates, Others Stumble
Resurrecting Cordis
Coronary Stents: Breaking J&J's Lock on the Market

Topics

Advertisement
UsernamePublicRestriction

Register

IV001891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel